
  
    
      
        Background_NNP
        Several_JJ anionic_JJ polymers_NNS were_VBD shown_VBN to_TO have_VB HIV-_NNP 1_CD
        inhibitory_NN activity_NN and_CC are_VBP being_VBG considered_VBN and_CC evaluated_VBN
        as_IN vaginal_JJ topical_JJ microbicides_NNS for_IN prevention_NN of_IN
        transmission_NN of_IN sexually_RB transmitted_VBD disease_NN (_( STD_NNP )_)
        pathogens_NNS ,_, including_VBG HIV-_NNP 1_CD ._. These_DT polymers_NNS belong_VBP to_TO
        several_JJ classes_NNS :_: (_( 1_LS )_) sulfate_NN esters_NNS of_IN polysaccharides_NNS
        (_( dextrin_NN and_CC dextran_NN sulfates_NNS [_NN 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD ]_NN ;_:
        cellulose_NN sulfate_NN [_NN 12_CD 13_CD 14_CD 15_CD ]_NN ;_: sulfate_NN esters_NNS of_IN
        galactose_NN +_NN 3_CD ,_, 6_CD -_: anhydrogalactose_NN copolymers_NNS {_( carrageenan_NN ;_: [_NN
        1_CD 16_CD 17_CD 18_CD 19_CD ]_NN }_) )_) ;_: (_( 2_LS )_) polymers_NNS containing_VBG sulfonated_JJ
        benzene_NN or_CC naphthalene_NN rings_NNS {_( poly_RB (_( styrene-_NN 4_CD -_: sulfonate_NN )_) [_NN
        20_CD 21_CD ]_NN }_) and_CC naphthalene_NN sulfonate_NN polymers_NNS {_( PRO_FW 2000_CD [_NN 22_CD
        23_CD 24_CD ]_NN }_) ;_: and_CC (_( 3_LS )_) polycarboxylates_NNS (_( acrylic_JJ acid_NN polymers_NNS
        {_( Carbomer_NNP 974_CD P_NN ;_: BufferGel_NNP [_NN 25_CD 26_CD 27_CD 28_CD 29_CD ]_NN }_) )_) ;_: and_CC acetyl_NN
        phthaloyl_NN cellulose_NN {_( cellulose_NN acetate_NN phthalate_NN (_( CAP_NNP )_) [_NN 30_CD
        31_CD 32_CD 33_CD 34_CD 35_CD 36_CD 37_CD ]_NN }_) ._.
        The_DT mechanisms_NNS involved_VBN in_IN sexual_JJ transmission_NN of_IN HIV-_NNP 1_CD
        appear_VB to_TO be_VB complex_JJ and_CC are_VBP not_RB yet_RB fully_RB defined_VBN [_NN 38_CD 39_CD
        ]_NN ._. Thus_RB ,_, a_DT microbicide_NN with_IN HIV-_NNP 1_CD inhibitory_NN activity_NN
        could_MD provide_VB protection_NN 
        in_IN vivo_NN only_RB if_IN both_DT the_DT compound_NN and_CC
        the_DT virus_NN reach_NN susceptible_JJ cells_NNS before_IN productive_JJ
        infection_NN could_MD occur_VB ._. This_DT might_MD be_VB difficult_JJ to_TO
        accomplish_VB ._. For_IN this_DT reason_NN ,_, it_PRP is_VBZ preferable_JJ that_IN
        microbicides_NNS irreversibly_RB inactivate_NN the_DT virus_NN upon_IN the_DT
        first_JJ compound_NN /_NN HIV-_NNP 1_CD encounter_VB in_IN the_DT vaginal_JJ environment_NN ,_,
        i_NNP ._. e_SYM ._. microbicides_NNS should_MD have_VB direct_JJ virucidal_NN activity_NN ._.
        Such_JJ activity_NN was_VBD reported_VBN for_IN dextran_NN sulfate_NN after_IN 2_CD h_NN
        incubation_NN with_IN HIV-_NNP 1_CD [_NN 2_CD ]_NN but_CC results_NNS of_IN other_JJ studies_NNS
        indicated_VBD that_DT dextran_NN sulfate_NN failed_VBD to_TO neutralize_NN virus_NN
        infectivity_NN [_NN 4_CD 10_CD ]_NN ._. Inactivation_NNP of_IN HIV-_NNP 1_CD by_IN carrageenan_NN
        was_VBD reported_VBN in_IN a_DT review_NN article_NN [_NN 18_CD ]_NN ._. BufferGel_NNP is_VBZ
        virucidal_NN against_IN HIV-_NNP 1_CD by_IN providing_VBG a_DT buffered_JJ low_JJ pH_NN
        environment_NN (_( pH_NN 3_CD ._. 9_CD [_NN 25_CD ]_NN )_) ,_, but_CC virus_NN inactivation_NN might_MD
        be_VB incomplete_JJ and_CC possibly_RB compromised_VBN by_IN minor_JJ pH_NN
        increases_NNS due_JJ to_TO the_DT presence_NN of_IN seminal_NN fluid_JJ [_NN 40_CD ]_NN ._. To_TO
        be_VB effective_JJ in_IN preventing_VBG infection_NN by_IN direct_JJ virus_NN
        inactivation_NN ,_, anti-_NN HIV-_NNP 1_CD microbicides_NNS must_MD be_VB virucidal_NN
        against_IN both_DT X_NNP 4_CD and_CC R_NN 5_CD viruses_NNS ,_, utilizing_VBG CXCR_NNP 4_CD and_CC CCR_NNP 5_CD as_IN
        coreceptors_NNS [_NN 39_CD 41_CD ]_NN ,_, respectively_RB ,_, R_NN 5_CD HIV-_NNP 1_CD being_VBG most_RBS
        frequently_RB sexually_RB transmitted_VBD ._. Recent_JJ results_NNS [_NN 36_CD 37_CD ]_NN ,_,
        (_( R_NN ._. Shattock_NNP ,_, personal_JJ communication_NN )_) indicate_VBP that_IN CAP_NNP in_IN
        soluble_JJ form_NN meets_VBZ these_DT requirements_NNS ._. Since_IN CAP_NNP ,_, unlike_IN
        the_DT other_JJ polymers_NNS listed_VBN above_IN ,_, is_VBZ not_RB soluble_JJ at_IN low_JJ pH_NN ,_,
        characteristic_JJ for_IN a_DT normal_JJ vaginal_JJ environment_NN [_NN 42_CD ]_NN ,_,
        micronized_JJ forms_NNS of_IN CAP_NNP had_VBD to_TO be_VB used_VBN in_IN microbicidal_NN
        formulations_NNS of_IN this_DT compound_NN [_NN 30_CD 31_CD 32_CD 33_CD 34_CD ]_NN ._.
        Therefore_RB ,_, it_PRP was_VBD of_IN interest_NN to_TO determine_VB how_WRB CAP_NNP in_IN
        micronized_JJ form_NN and_CC other_JJ candidate_NN polymeric_JJ microbicides_NNS
        affect_VBP X_NNP 4_CD and_CC R_NN 5_CD viruses_NNS represented_VBN by_IN HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP ,_,
        respectively_RB ._.
      
      
        Methods_NNP
        
          Reagents_NNP
          Aquateric_NNP (_( the_DT micronized_JJ form_NN of_IN CAP_NNP containing_VBG ≈_NN 66_CD %_NN
          CAP_NNP and_CC ≈_NN 34_CD %_NN of_IN Poloxamer_NNP and_CC distilled_VBN acetylated_JJ
          monoglycerides_NNS )_) was_VBD obtained_VBN from_IN the_DT FMC_NNP Corporation_NNP ,_,
          Philadelphia_NNP ,_, PA_NNP ._. Cellulose_NNP acetate_NN phthalate_NN (_( CAP_NNP )_) was_VBD a_DT
          gift_NN from_IN Eastman_NNP Chemical_NNP Company_NNP ,_, Kingsport_NNP ,_, TN_NNP ,_, and_CC
          micronized_JJ using_VBG a_DT SPEX_NNP 6800_CD freezer_NN mill_NN (_( SPEX_NNP
          CertiPrep_NNP ,_, Metuchen_NNP ,_, NJ_NNP )_) with_IN the_DT following_JJ settings_NNS :_:
          precooling_VBG time_NN 10_CD min_NN ,_, cooling_VBG time_NN 1_CD min_NN ,_, input_NN
          frequency_NN 15_CD ;_: 3_CD cycles_NNS of_IN 3_CD min_NN each_DT ._. The_DT following_VBG
          additional_JJ polymers_NNS were_VBD obtained_VBN from_IN commercial_JJ sources_NNS
          likely_JJ to_TO be_VB different_JJ from_IN those_DT for_IN proprietary_JJ
          products_NNS being_VBG developed_VBN as_IN microbicides_NNS :_: carrageenans_NNS κ_NN
          and_CC λ_NN (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP ;_: mixed_JJ at_IN a_DT 1_CD :_: 1_CD (_( w_NN /_NN w_NN )_) ratio_NN
          in_IN all_DT experiments_NNS )_) ;_: cellulose_NN sulfate_NN (_( Across_IN Organics_NNP ,_,
          Piscataway_NNP ,_, NJ_NNP )_) ;_: dextran_NN sulfate_NN (_( M_NNP ._. W_NNP ._. 500_CD ,_, 000_CD ;_:
          Pharmacia_NNP ,_, Kalamazoo_NNP ,_, MI_NNP )_) ;_: poly_RB (_( naphthalene_NN sulfonate_NN )_)
          (_( BASF_NNP ,_, Parsippany_NNP ,_, NJ_NNP )_) ;_: poly_RB (_( styrene-_NN 4_CD -_: sulfonate_NN )_)
          (_( Polysciences_NNP ,_, Inc_NNP ._. ,_, Warrington_NNP ,_, PA_NNP )_) ;_: and_CC Carbomer_NNP 974_CD P_NN
          (_( B_NNP ._. F_NN ._. Goodrich_NNP ,_, Cleveland_NNP ,_, OH_NNP )_) ._. Poloxamer_NNP {_( an_DT
          α-_NN Hydro-γ-hydroxypoly_NNP (_( oxyethylene_NN )_) poly_RB (_( oxypropylene_NN )_) poly_RB (_( oxyethylene_NN )_)
          block_VB copolymer_NN }_) was_VBD from_IN Spectrum_NNP ,_, New_NNP Brunswick_NNP ,_, NJ_NNP ._.
          Goat_NNP serum_NN was_VBD from_IN Atlanta_NNP Biologicals_NNP ,_, Norcross_NNP ,_, CA_NNP ._.
          BufferGel_NNP was_VBD a_DT gift_NN from_IN Dr_NNP ._. Kevin_NNP J_NNP ._. Whaley_NNP ,_, John_NNP
          Hopkins_NNP University_NNP ._. The_DT mouse_NN monoclonal_NN antibody_NN (_( mAb_NN )_) ,_,
          NC-_NNP 1_CD ,_, raised_VBD against_IN the_DT gp_NN 41_CD six_CD /_NN helix_NN bundle_NN from_IN HIV-_NNP 1_CD
          IIIB_NNP was_VBD prepared_VBN as_IN described_VBN [_NN 43_CD ]_NN and_CC shown_VBN to_TO react_VB
          also_RB with_IN six-helix_JJ bundles_NNS from_IN HIV-_NNP 1_CD BaL_NNP [_NN 37_CD ]_NN ._.
          Rabbit_NNP antibodies_NNS against_IN the_DT gp_NN 41_CD six-helix_JJ bundle_NN and_CC
          against_IN HIV-_NNP 1_CD IIIB_NNP gp_NN 120_CD were_VBD prepared_VBN as_IN described_VBN [_NN 44_CD
          45_CD ]_NN ._. The_DT latter_JJ antibodies_NNS were_VBD shown_VBN to_TO crossreact_NN
          with_IN HIV-_NNP 1_CD BaL_NNP gp_NN 120_CD [_NN 37_CD ]_NN ._. Rabbit_NNP antibodies_NNS against_IN
          HIV-_NNP 1_CD tat_NN as_RB well_RB as_IN recombinant_JJ HIV-_NNP 1_CD IIIB_NNP gp_NN 120_CD and_CC
          biotinylated_JJ soluble_JJ CD_NNP 4_CD (_( sCD_NN 4_LS )_) were_VBD from_IN
          ImmunoDiagnostics_NNP ,_, Inc_NNP ._. ,_, Woburn_NNP ,_, MA_NNP ._. Horseradish_NNP
          peroxidase_NN (_( HRP_NNP )_) labeled_VBN streptavidin_NN was_VBD from_IN Zymed_NNP ,_,
          South_NNP San_NNP Francisco_NNP ,_, CA_NNP ._. HRP_NNP labeled_VBD goat_NN anti-rabbit_JJ IgG_NNP
          was_VBD from_IN Southern_NNP Biotechnology_NNP Associates_NNPS ,_, Inc_NNP ._. ,_,
          Birmingham_NNP ,_, AL_NNP ._. HRP_NNP was_VBD quantitated_JJ using_VBG a_DT kit_NN from_IN
          Kirkegaard_NNP &_CC Perry_NNP Laboratories_NNPS ,_, Inc_NNP ._. ,_, Gaithersburg_NNP ,_,
          MD_NNP ._. Biotin_NNP labeled_VBD mouse_NN IgG_NNP was_VBD obtained_VBN from_IN the_DT Roche_NNP
          Diagnostics_NNPS Corporation_NNP ,_, Indianapolis_NNP ,_, IN_IN ._. Recombinant_NNP
          protein_NN A_DT /_NN G_NNP was_VBD from_IN Pierce_NNP ,_, Rockford_NNP ,_, IL_NNP ._. Enzyme_NNP linked_VBD
          immunosorbent_NN assay_NN (_( ELISA_NNP )_) kits_NNS for_IN the_DT HIV-_NNP 1_CD p_NN 24_CD
          antigen_NN were_VBD from_IN Beckman_NNP Coulter_NNP ,_, Inc_NNP ._. ,_, Miami_NNP ,_, FL_NNP ._.
          Pelletted_NNP ,_, 1000_CD -_: fold_VB concentrates_VBZ of_IN HIV-_NNP 1_CD IIIB_NNP (_( 6_CD ._. 8_CD ×_NN 10_CD
          10_CD virus_NN particles_NNS /_NN ml_NN )_) and_CC BaL_NNP (_( 2_CD ._. 47_CD ×_NN 10_CD 10_CD virus_NN
          particles_NNS /_NN ml_NN )_) [_NN 46_CD ]_NN were_VBD from_IN Advanced_NNP Biotechnologies_NNP ,_,
          Inc_NNP ._. ,_, Colombia_NNP ,_, MD_NNP ._. Human_JJ seminal_NN fluid_NN was_VBD purchased_VBN
          from_IN New_NNP England_NNP Immunology_NNP Associates_NNPS ,_, Cambridge_NNP ,_, MA_NNP ._.
          HeLa-CD_NNP 4_CD -_: LTR-β-gal_NNP and_CC MAGI-CCR_NNP 5_CD cells_NNS were_VBD obtained_VBN from_IN
          the_DT AIDS_NNP Research_NNP and_CC Reference_NNP Reagent_NNP Program_NN
          contributed_VBN by_IN Drs_NNP ._. M_NNP ._. Emerman_NNP and_CC J_NNP ._. Overbaugh_NNP ._.
          Dulbecco_NNP 's_POS modified_VBN Eagle_NNP medium_NN (_( DMEM_NNP )_) was_VBD from_IN GIBCO_NNP ™_NN
          Invitrogen_NNP Corporation_NNP ,_, Carlsbad_NNP ,_, CA_NNP ._. The_DT Galacto-_NNP Light_NNP
          Plus_NNP chemiluminescence_NN reporter_NN assay_NN for_IN β-galactosidase_JJ
          was_VBD from_IN Applied_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP ._.
          Citrate_NNP /_NN phosphate_NN buffers_NNS in_IN the_DT pH_NN range_NN of_IN 2_CD ._. 9_CD -_: 5_CD ._. 0_CD
          were_VBD prepared_VBN as_IN described_VBN [_NN 47_CD ]_NN ._.
        
        
          Enzyme-linked_NNP immunosorbent_NN assays_NNS (_( ELISA_NNP )_)
          The_DT sandwich_NN ELISA_NNP for_IN gp_NN 41_CD six-helix_JJ bundles_NNS was_VBD
          performed_VBN as_IN described_VBN [_NN 37_CD 45_CD ]_NN ._. HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP
          virus_NN preparations_NNS ,_, respectively_RB ,_, treated_VBN with_IN distinct_JJ
          anionic_JJ polymers_NNS ,_, were_VBD precipitated_VBD with_IN 3_CD %_NN polyethylene_NN
          glycol_NN 6000_CD (_( PEG_NNP )_) in_IN order_NN to_TO separate_VB virus_NN particles_NNS
          from_IN excess_JJ compounds_NNS ._. The_DT pellets_NNS were_VBD dissolved_VBN in_IN
          lysis_NNS buffer_NN [_NN 1_CD %_NN Nonidet_NNP P_NN 40_CD {_( NP_NNP 40_CD }_) ,_, 100_CD μg_NN /_NN ml_NN bovine_JJ
          serum_NN albumin_NN (_( BSA_NNP )_) in_IN phosphate_NN buffered_JJ saline_NN (_( PBS_NNP )_) ]_NN ,_,
          incubated_JJ for_IN 30_CD min_NN at_IN 20_CD °_NN C_NNP and_CC then_RB added_VBD to_TO wells_NNS
          coated_VBN with_IN rabbit_NN polyclonal_NN antibodies_NNS to_TO the_DT gp_NN 41_CD
          core_NN ._. Control_NN virus_NN was_VBD treated_VBN similarly_RB ._. The_DT lysis_NNS
          buffer_NN was_VBD used_VBN as_IN a_DT safety_NN precaution_NN to_TO minimize_VB work_NN
          with_IN potentially_RB infectious_JJ virus_NN ._. Similar_JJ results_NNS were_VBD
          obtained_VBN when_WRB PBS_NNP was_VBD used_VBN for_IN resuspension_NN of_IN virus_NN
          particles_NNS instead_RB of_IN lysis_NNS buffer_NN ._. After_IN incubation_NN at_IN
          4_CD °_NN C_NNP overnight_JJ ,_, the_DT bound_VBN six-helix_JJ bundles_NNS were_VBD detected_VBN
          by_IN adding_VBG mAb_NN NC-_NNP 1_CD (_( 1_CD μg_NN /_NN ml_NN in_IN PBS_NNP /_NN 1_CD %_NN BSA_NNP /_NN 1_CD %_NN gelatin_NN {_( 100_CD
          μl_NN /_NN well_RB }_) for_IN 1_CD h_NN at_IN 37_CD °_NN C_NNP ._. Subsequently_NNP the_DT wells_NNS were_VBD
          washed_VBN three_CD times_NNS with_IN PBS_NNP /_NN 0_CD ._. 05_CD %_NN Tween_NNP 20_CD ,_, and_CC biotin_NN
          labeled_VBD anti-mouse_JJ IgG_NNP (_( 100_CD μl_NN /_NN well_RB ;_: 125_CD ng_NN /_NN ml_NN diluted_VBN in_IN
          PBS_NNP containing_VBG 1_CD %_NN dry_JJ fat-free_JJ milk_NN )_) was_VBD added_VBN ._. After_IN
          incubation_NN for_IN 1_CD h_NN at_IN 37_CD °_NN C_NNP the_DT wells_NNS were_VBD washed_VBN and_CC
          HRP-streptavidin_NNP (_( 125_CD ng_NN /_NN ml_NN in_IN PBS_NNP containing_VBG 10_CD %_NN goat_NN
          serum_NN ;_: 100_CD μl_NN /_NN well_RB )_) was_VBD added_VBN ._. After_IN incubation_NN for_IN 1_CD h_NN
          at_IN 37_CD °_NN C_NNP ,_, the_DT wells_NNS were_VBD washed_VBN six_CD times_NNS with_IN PBS_NNP /_NN 0_CD ._. 05_CD %_NN
          Tween_NNP 20_CD ._. Bound_NNP HRP_NNP was_VBD detected_VBN using_VBG the_DT test_NN kit_NN from_IN
          Kirkegaard_NNP &_CC Perry_NNP Laboratories_NNPS following_VBG the_DT
          manufacturer_NN 's_POS protocol_NN ,_, and_CC the_DT absorbance_NN was_VBD read_VBN at_IN
          450_CD nm_NN ._.
          Recombinant_NNP gp_NN 120_CD HIV-_NNP 1_CD IIIB_NNP in_IN the_DT presence_NN of_IN a_DT
          10_CD -_: fold_VB excess_NN of_IN BSA_NNP and_CC gelatin_NN ,_, respectively_RB ,_, was_VBD
          quantitated_JJ by_IN adding_VBG the_DT gp_NN 120_CD /_NN BSA_NNP /_NN gelatin_NN mixtures_NNS
          (_( before_IN and_CC after_IN binding_JJ to_TO micronized_JJ CAP_NNP or_CC Aquateric_NNP ;_:
          Fig_NNP ._. 1_LS )_) at_IN serial_NN 5_CD -_: fold_VB dilutions_NNS (_( 2_CD -_: fold_VB to_TO 3_CD ._. 9_CD ×_NN 10_CD
          6_CD -_: fold_VB in_IN 0_CD ._. 14_CD M_NNP NaCl-_NNP 0_CD ._. 01_CD M_NNP Tris_NNP {_( TS_NNP }_) )_) to_TO 96_CD -_: well_RB
          polystyrene_NN plates_NNS (_( Immulon_NNP II_NNP ,_, Dynatech_NNP Laboratories_NNPS ,_,
          Inc_NNP ._. Chantilly_NNP ,_, VA_NNP )_) ._. After_IN overnight_JJ incubation_NN at_IN 4_CD °_NN C_NNP ,_,
          the_DT wells_NNS were_VBD washed_VBN and_CC rabbit_NN anti-gp_JJ 120_CD (_( diluted_VBN
          1_CD :_: 1_CD ,_, 000_CD in_IN 20_CD %_NN goat_NN serum_NN -_: 0_CD ._. 05_CD %_NN Tween_NNP 20_CD in_IN PBS_NNP pH_NN 7_CD ._. 4_LS )_)
          was_VBD added_VBN ._. After_IN 2_CD h_NN at_IN 37_CD °_NN C_NNP the_DT wells_NNS were_VBD washed_VBN and_CC
          HRP_NNP labeled_VBD goat_NN anti-rabbit_JJ IgG_NNP (_( diluted_VBN in_IN 1_CD %_NN BSA_NNP -_:
          0_CD ._. 25_CD %_NN gelatin_NN -_: 0_CD ._. 05_CD %_NN Tween_NNP 20_CD in_IN PBS_NNP pH_NN 7_CD ._. 4_CD ;_: {_( 250_CD
          ng_NN /_NN well_RB }_) )_) was_VBD added_VBN ._. After_IN 2_CD h_NN at_IN 37_CD °_NN C_NNP bound_VBN HRP_NNP was_VBD
          detected_VBN using_VBG the_DT kit_NN from_IN Kirkegaard_NNP &_CC Perry_NNP
          Laboratories_NNPS ._. The_DT quantity_NN of_IN gp_NN 120_CD not_RB adsorbed_JJ to_TO
          CAP_NNP /_NN Aquateric_NNP was_VBD determined_VBN from_IN calibration_NN curves_NNS
          relating_VBG absorbance_NN readings_NNS to_TO the_DT concentration_NN of_IN
          gp_NN 120_CD not_RB exposed_VBN to_TO CAP_NNP /_NN Aquateric_NNP ._.
          The_DT envelope_NN glycoprotein_NN gp_NN 120_CD released_VBN from_IN HIV-_NNP 1_CD
          BaL_NNP was_VBD quantitated_JJ as_IN follows_VBZ :_: Wells_NNP of_IN polystyrene_NN
          plates_NNS were_VBD first_JJ coated_VBN with_IN protein_NN A_DT /_NN G_NNP (_( 1_CD μg_NN /_NN well_RB )_) in_IN
          0_CD ._. 1_CD M_NNP Tris_NNP buffer_NN ,_, pH_NN 8_CD ._. 8_CD for_IN 2_CD h_NN at_IN 20_CD °_NN C_NNP followed_VBN by_IN
          polyclonal_NN rabbit_NN anti-gp_JJ 120_CD (_( diluted_VBN 500_CD -_: fold_VB )_) for_IN 1_CD h_NN
          at_IN 20_CD °_NN C_NNP ._. Serial_JJ 2_CD -_: fold_VB dilutions_NNS in_IN PBS_NNP containing_VBG 1_CD %_NN BSA_NNP
          and_CC 1_CD %_NN gelatin_NN (_( PBS-BG_NNP )_) of_IN preparations_NNS containing_VBG gp_NN 120_CD
          were_VBD added_VBN to_TO the_DT wells_NNS ._. After_IN 4_CD h_NN at_IN 20_CD °_NN C_NNP the_DT wells_NNS were_VBD
          washed_VBN and_CC bound_VBN gp_NN 120_CD was_VBD detected_VBN by_IN addition_NN of_IN
          biotinyl_NN sCD_NN 4_CD (_( 1_CD μg_NN )_) followed_VBN by_IN HRP_NNP streptavidin_NN ._. Bound_NNP
          HRP_NNP was_VBD quantitated_JJ as_IN described_VBN above_IN ._. The_DT experiments_NNS
          were_VBD done_VBN in_IN triplicate_NN ._.
        
        
          Measurements_NNP of_IN HIV-_NNP 1_CD infectivity_NN
          Two-fold_NNP serial_NN dilutions_NNS of_IN HIV-_NNP 1_CD IIIB_NNP treated_VBD with_IN
          distinct_JJ anionic_JJ polymers_NNS ,_, and_CC separated_JJ from_IN these_DT
          polymers_NNS by_IN precipitation_NN with_IN 3_CD %_NN PEG_NNP or_CC by_IN
          centrifugation_NN at_IN 14_CD ,_, 000_CD rpm_NN for_IN 1_CD h_NN ,_, and_CC control_NN virus_NN
          (_( 100_CD μl_NN )_) ,_, respectively_RB ,_, were_VBD added_VBN to_TO HeLa-CD_NNP 4_CD -_: LTR-β-gal_NNP
          cells_NNS which_WDT had_VBD been_VBN plated_JJ a_DT day_NN before_IN infection_NN in_IN
          96_CD -_: well_RB plates_NNS at_IN 1_CD ×_NN 10_CD 4_CD cells_NNS /_NN well_RB in_IN 100_CD μl_NN of_IN DMEM_NNP
          medium_NN containing_VBG 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) ._. In_IN some_DT
          experiments_NNS ,_, anti-_NN HIV-_NNP 1_CD tat_NN IgG_NNP (_( 25_CD μg_NN )_) was_VBD added_VBN to_TO
          treated_VBN and_CC control_NN virus_NN to_TO suppress_VB the_DT effect_NN of_IN
          extracellular_NN tat_NN ,_, which_WDT may_MD have_VB been_VBN present_JJ in_IN the_DT
          virus_NN preparations_NNS ,_, on_IN virus_NN infection_NN [_NN 48_CD 49_CD ]_NN ._. After_IN
          incubation_NN at_IN 37_CD °_NN C_NNP for_IN 48_CD h_NN ,_, the_DT culture_NN supernatant_NN
          fluids_NNS were_VBD removed_VBN and_CC the_DT cells_NNS washed_VBN once_RB with_IN PBS_NNP ._.
          Subsequently_RB ,_, 50_CD μl_NN of_IN lysis_NNS buffer_NN from_IN the_DT
          Galacto-_NNP Light_NNP Plus_NNP kit_NN were_VBD added_VBN to_TO the_DT wells_NNS for_IN 1_CD h_NN at_IN
          20_CD °_NN C_NNP ._. Aliquots_NNP (_( 20_CD μl_NN )_) of_IN the_DT cell_NN lysates_NNS were_VBD
          transferred_VBN into_IN wells_NNS of_IN 96_CD -_: well_RB microplates_NNS and_CC
          β-galactosidase_JJ was_VBD quantitated_JJ using_VBG the_DT Galacto-_NNP Light_NNP
          Plus_NNP System_NNP chemiluminescence_NN reporter_NN assay_NN in_IN a_DT
          Microlight_NNP ML_NNP 2250_CD luminometer_NN (_( Dynatech_NNP Laboratories_NNPS ,_,
          Inc_NNP ._. Chantilly_NNP ,_, VA_NNP )_) ._. The_DT infectivity_NN of_IN treated_VBN and_CC
          control_NN HIV-_NNP 1_CD BaL_NNP was_VBD measured_VBN by_IN the_DT same_JJ method_NN except_IN
          that_DT MAGI-CCR_NNP 5_CD cells_NNS were_VBD used_VBN ._.
          Measurement_NNP of_IN HIV-_NNP 1_CD infectivity_NN in_IN seminal_NN fluid_NN is_VBZ
          impeded_VBN by_IN the_DT cytotoxicity_NN of_IN seminal_NN plasma_NN [_NN 50_CD 51_CD ]_NN ._.
          contributed_VBD to_TO by_IN spermine_NN [_NN 52_CD ]_NN ._. Such_JJ effects_NNS were_VBD
          minimized_VBN by_IN using_VBG for_IN titrations_NNS of_IN virus_NN infectivity_NN
          pellets_NNS after_IN precipitation_NN with_IN 3_CD %_NN PEG_NNP or_CC after_IN
          centrifugation_NN (_( 14_CD ,_, 000_CD rpm_NN for_IN 1_CD h_NN )_) ._.
        
      
      
        Results_NNS
        
          Micronized_NNP CAP_NNP induces_VBZ gp_NN 41_CD six-helix_JJ bundle_NN
          formation_NN and_CC is_VBZ virucidal_NN against_IN HIV-_NNP 1_CD
          Earlier_JJR studies_NNS [_NN 36_CD 37_CD ]_NN ._. indicated_VBD that_IN soluble_JJ CAP_NNP
          at_IN neutral_JJ pH_NN binds_NNS to_TO the_DT CXCR_NNP 4_CD and_CC CCR_NNP 5_CD coreceptor_NN
          binding_JJ sites_NNS on_IN HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP ,_, respectively_RB ,_, and_CC
          induced_VBD the_DT formation_NN of_IN "_'' dead-end_JJ "_'' gp_NN 41_CD six-helix_JJ
          bundles_NNS ._. These_DT two_CD properties_NNS of_IN soluble_JJ CAP_NNP appear_VBP to_TO be_VB
          involved_VBN in_IN the_DT virus_NN inhibitory_NN and_CC virucidal_NN activities_NNS
          of_IN this_DT compound_NN ._. However_RB ,_, CAP_NNP is_VBZ not_RB soluble_JJ at_IN <_NN pH_NN
          5_CD ._. 5_CD and_CC would_MD precipitate_NN in_IN a_DT healthy_JJ human_JJ vaginal_JJ
          environment_NN which_WDT is_VBZ mildly_RB acidic_JJ with_IN a_DT pH_NN range_NN of_IN 3_CD ._. 5_CD
          -_: 4_CD ._. 5_CD [_NN 53_CD ]_NN ._. The_DT precipitate_NN would_MD have_VB drastically_RB
          reduced_VBN antiviral_JJ activity_NN ._. To_TO overcome_VB this_DT problem_NN ,_, CAP_NNP
          in_IN a_DT micronized_JJ form_NN was_VBD used_VBN and_CC proven_VBN to_TO have_VB
          virucidal_NN activity_NN against_IN HIV-_NNP 1_CD IIIB_NNP [_NN 31_CD ]_NN and_CC shown_VBN to_TO
          be_VB effective_JJ in_IN reducing_VBG vaginal_JJ infection_NN by_IN simian_NN
          immunodeficiency_NN virus_NN (_( SIV_NNP )_) in_IN a_DT macaque_NN model_NN [_NN 34_CD ]_NN ._.
          Micronized_NNP CAP_NNP provides_VBZ a_DT low_JJ pH_NN buffering_VBG system_NN and_CC
          this_DT may_MD have_VB contributed_VBN to_TO its_PRP$ virucidal_NN properties_NNS ._. In_IN
          order_NN to_TO correlate_VBP the_DT properties_NNS of_IN CAP_NNP in_IN soluble_JJ and_CC
          micronized_JJ forms_NNS ,_, it_PRP was_VBD necessary_JJ to_TO establish_VB whether_IN
          or_CC not_RB micronized_JJ CAP_NNP would_MD bind_NN HIV-_NNP 1_CD virus_NN particles_NNS
          and_CC HIV-_NNP 1_CD envelope_NN glycoproteins_NNS ,_, and_CC induce_VB the_DT
          formation_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS ,_, a_DT marker_NN of_IN
          irreversible_JJ virus_NN inactivation_NN ,_, as_IN did_VBD soluble_JJ CAP_NNP [_NN 37_CD
          ]_NN ._. First_CD it_PRP was_VBD established_VBN that_IN HIV-_NNP 1_CD gp_NN 120_CD bound_VBN to_TO
          micronized_JJ CAP_NNP (_( provided_VBN in_IN the_DT form_NN of_IN micronized_JJ CAP_NNP
          particles_NNS or_CC of_IN a_DT commercial_JJ product_NN ,_, "_'' Aquateric_NNP "_'' ,_,
          containing_VBG about_IN 66_CD %_NN of_IN CAP_NNP and_CC used_VBN for_IN enteric_JJ coating_NN
          of_IN tablets_NNS and_CC capsules_NNS in_IN the_DT pharmaceutical_JJ industry_NN [_NN
          54_CD ]_NN )_) ;_: (_( Fig_NNP ._. 1_LS )_) ._. Similar_JJ results_NNS were_VBD obtained_VBN when_WRB
          gp_NN 120_CD was_VBD diluted_VBN in_IN seminal_NN fluid_JJ (_( diluted_VBN 1_CD :_: 1_CD with_IN 0_CD ._. 14_CD
          M_NNP NaCl_NNP )_) ._. Under_IN these_DT conditions_NNS ,_, ≥_NN 99_CD ._. 9997_CD %_NN of_IN gp_NN 120_CD
          bound_VBN to_TO micronized_JJ CAP_NNP and_CC Aquateric_NNP (_( final_JJ
          concentration_NN of_IN CAP_NNP :_: 121_CD ._. 5_LS mg_NN /_NN ml_NN )_) ,_, respectively_RB ._. HIV-_NNP 1_CD
          IIIB_NNP and_CC BaL_NNP virus_NN particles_NNS also_RB bound_VBN effectively_RB in_IN
          the_DT presence_NN of_IN seminal_NN fluid_JJ to_TO Aquateric_NNP formulated_VBN
          into_IN a_DT topical_JJ gel_NN (_( Fig_NNP ._. 2_LS )_) ._.
          As_IN a_DT result_NN of_IN interaction_NN with_IN micronized_JJ CAP_NNP (_( in_IN the_DT
          form_NN of_IN Aquateric_NNP )_) ,_, the_DT integrity_NN of_IN both_DT HIV-_NNP 1_CD IIIB_NNP and_CC
          HIV-_NNP 1_CD BaL_NNP virus_NN particles_NNS was_VBD strikingly_RB affected_VBN as_IN
          indicated_VBN by_IN the_DT observation_NN that_IN most_JJS of_IN the_DT p_NN 24_CD antigen_NN
          after_IN virus_NN contact_NN with_IN micronized_JJ CAP_NNP was_VBD no_DT longer_RB
          precipitable_JJ by_IN 3_CD %_NN polyethylene_NN glycol_NN 6000_CD (_( PEG_NNP )_) unlike_IN
          p_NN 24_CD antigen_NN within_IN untreated_JJ virus_NN particles_NNS which_WDT
          precipitates_NNS under_IN these_DT conditions_NNS (_( Fig_NNP ._. 3_LS )_) ._.
          Furthermore_RB ,_, interaction_NN with_IN micronized_JJ CAP_NNP elicited_JJ the_DT
          formation_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS which_WDT were_VBD
          undetectable_JJ or_CC present_JJ at_IN low_JJ levels_NNS in_IN untreated_JJ virus_NN
          particles_NNS [_NN 37_CD ]_NN ._. The_DT six-helix_JJ bundles_NNS detectable_JJ by_IN
          ELISA_NNP were_VBD mostly_RB not_RB precipitable_JJ by_IN 3_CD %_NN PEG_NNP indicating_VBG
          that_IN they_PRP were_VBD no_RB longer_RB associated_VBN with_IN virus_NN particles_NNS
          (_( Fig_NNP ._. 3_LS )_) ._. Furthermore_RB ,_, they_PRP were_VBD detected_VBN partially_RB
          (_( HIV-_NNP 1_CD IIIB_NNP )_) or_CC entirely_RB (_( HIV-_NNP 1_CD BaL_NNP )_) in_IN a_DT form_NN not_RB bound_VBN
          anymore_RB to_TO the_DT micronized_JJ CAP_NNP particles_NNS ,_, unlike_IN most_JJS of_IN
          the_DT virus-derived_JJ p_NN 24_CD antigen_NN ._. This_DT suggests_VBZ that_DT
          interaction_NN of_IN virus_NN particles_NNS with_IN micronized_JJ CAP_NNP
          resulted_VBD in_IN stripping_VBG off_RP of_IN the_DT viral_JJ envelopes_NNS which_WDT
          was_VBD more_RBR noticeable_JJ with_IN HIV-_NNP 1_CD BaL_NNP than_IN with_IN HIV-_NNP 1_CD
          IIIB_NNP ._.
          To_TO confirm_VB that_DT gp_NN 41_CD six_CD helix_NN bundle_NN formation_NN was_VBD
          caused_VBN by_IN contact_NN of_IN virus_NN particles_NNS with_IN the_DT micronized_JJ
          form_NN of_IN CAP_NNP (_( =_SYM Aquateric_NNP )_) and_CC not_RB by_IN low_JJ pH_NN contributed_VBN
          by_IN CAP_NNP ,_, purified_JJ HIV-_NNP 1_CD III_NNP B_NNP and_CC BaL_NNP ,_, respectively_RB ,_, was_VBD
          exposed_VBN for_IN 5_CD min_NN at_IN 37_CD °_NN C_NNP to_TO acidic_JJ buffers_NNS (_( final_JJ pH_NN
          2_CD ._. 9_CD ,_, 3_CD ._. 5_CD ,_, 4_CD ._. 0_CD ,_, 4_CD ._. 5_CD and_CC 5_CD ._. 0_CD )_) ._. The_DT suspensions_NNS were_VBD
          neutralized_VBN and_CC assayed_JJ by_IN ELISA_NNP for_IN six-helix_JJ bundles_NNS ._.
          The_DT results_NNS were_VBD negative_JJ (_( absorbance_NN in_IN the_DT 0_CD to_TO 0_CD ._. 068_CD
          range_NN ,_, the_DT same_JJ as_IN for_IN viruses_NNS exposed_VBN to_TO pH_NN 7_CD ._. 0_CD in_IN the_DT
          absence_NN of_IN CAP_NNP )_) ._. Poloxamer_NNP ,_, a_DT constituent_NN of_IN Aquateric_NNP (_( ≤_NN
          33_CD %_NN )_) at_IN a_DT final_JJ concentration_NN of_IN 30_CD mg_NN /_NN ml_NN also_RB did_VBD not_RB
          induce_VB the_DT formation_NN of_IN six-helix_JJ bundles_NNS ._.
          Results_NNS shown_VBN above_IN indicated_VBD that_IN HIV-_NNP 1_CD adsorbed_JJ onto_IN
          micronized_JJ CAP_NNP and_CC that_IN the_DT CAP_NNP -_: virus_NN interaction_NN lead_NN
          to_TO the_DT formation_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS ,_, a_DT hallmark_NN
          for_IN HIV-_NNP 1_CD inactivation_NN ._. [_NN 37_CD ]_NN To_TO confirm_VB that_DT contact_NN of_IN
          virus_NN with_IN micronized_JJ CAP_NNP leads_VBZ to_TO loss_NN of_IN HIV-_NNP 1_CD
          infectivity_NN ,_, HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP ,_, respectively_RB ,_, were_VBD
          diluted_VBN in_IN seminal_NN fluid_JJ and_CC the_DT diluted_VBN virus_NN
          preparations_NNS were_VBD mixed_VBN with_IN an_DT Aquateric_NNP formulation_NN
          (_( for_IN composition_NN ,_, see_VB legend_NN to_TO Fig_NNP ._. 2_LS )_) at_IN volume_NN ratios_NNS
          of_IN 3_CD :_: 1_CD ,_, 1_CD :_: 1_CD and_CC 1_CD :_: 3_CD for_IN 5_CD min_NN at_IN 37_CD °_NN C_NNP ._. Subsequently_RB ,_, the_DT
          micronized_JJ Aquateric_NNP particles_NNS were_VBD sedimented_JJ by_IN
          centrifugation_NN ._. The_DT supernatant_NN fluids_NNS were_VBD brought_VBN to_TO pH_NN
          7_CD ._. 0_CD and_CC the_DT pellets_NNS were_VBD dissolved_VBN by_IN addition_NN of_IN Na_NNP 
          3_CD PO_NNP 
          4_CD (_( final_JJ pH_NN =_SYM 7_CD ._. 0_CD )_) ._. All_DT fractions_NNS were_VBD
          then_RB precipitated_VBD by_IN 3_CD %_NN PEG_NNP and_CC the_DT redissolved_JJ pellets_NNS
          tested_VBN at_IN 2_CD -_: to_TO 256_CD -_: fold_VB dilutions_NNS for_IN infectivity_NN (_( see_VB
          Methods_NNP section_NN )_) ._. Infectious_NNP virus_NN was_VBD undetectable_JJ (_( ≥_NN
          99_CD ._. 6_CD %_NN and_CC ≥_NN 99_CD ._. 2_LS %_NN inactivation_NN of_IN HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP ,_,
          respectively_RB )_) ._. Similar_JJ results_NNS were_VBD obtained_VBN with_IN other_JJ
          CAP_NNP formulations_NNS (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Induction_NNP of_IN six-helix_JJ bundle_NN formation_NN by_IN
          polymeric_JJ anionic_JJ candidate_NN microbicides_NNS
          Since_IN elicitation_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS might_MD be_VB
          involved_VBN in_IN ,_, or_CC contribute_VB to_TO the_DT virucidal_NN activity_NN of_IN
          candidate_NN microbicides_NNS ,_, it_PRP was_VBD of_IN interest_NN to_TO determine_VB
          whether_IN anionic_JJ polymers_NNS other_JJ than_IN CAP_NNP also_RB induced_VBD
          six-helix_JJ bundle_NN formation_NN in_IN HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP virus_NN
          particles_NNS ._.
          Results_NNS in_IN Fig_NNP ._. 4_LS show_NN that_DT carrageenan_NN ,_, cellulose_NN
          sulfate_NN ,_, dextran_NN sulfate_NN ,_, poly_RB (_( napthalene_NN sulfonate_NN )_) and_CC
          poly_RB (_( styrene-_NN 4_CD -_: sulfonate_NN )_) all_DT elicit_NN gp_NN 41_CD six-helix_JJ
          bundle_NN formation_NN in_IN HIV-_NNP 1_CD IIIB_NNP but_CC somewhat_RB less_RBR
          effectively_RB in_IN comparison_NN with_IN CAP_NNP ._. On_IN the_DT other_JJ hand_NN ,_,
          Carbomer_NNP 974_CD P_NN ,_, the_DT active_JJ ingredient_NN in_IN BufferGel_NNP ,_, was_VBD
          inactive_JJ in_IN this_DT respect_NN ._. Strikingly_NNP different_JJ results_NNS
          were_VBD obtained_VBN for_IN HIV-_NNP 1_CD BaL_NNP (_( Fig_NNP ._. 5_LS )_) ,_, and_CC show_NN that_IN only_RB
          CAP_NNP and_CC to_TO a_DT lesser_JJR extent_NN poly_RB (_( napthalene_NN sulfonate_NN )_)
          elicited_JJ gp_NN 41_CD six-helix_JJ bundles_NNS detectable_JJ by_IN ELISA_NNP ._.
        
        
          Effect_NN of_IN anionic_JJ polymeric_JJ microbicide_NN candidates_NNS
          on_IN the_DT integrity_NN of_IN HIV-_NNP 1_CD particles_NNS
          Since_IN micronized_JJ CAP_NNP caused_VBD the_DT dissociation_NN of_IN HIV-_NNP 1_CD
          particles_NNS [_NN 31_CD ]_NN ;_: (_( Fig_NNP ._. 3_LS )_) ,_, it_PRP was_VBD of_IN interest_NN to_TO
          determine_VB whether_IN anionic_JJ polymeric_JJ candidate_NN
          microbicides_NNS in_IN soluble_JJ form_NN at_IN neutral_JJ pH_NN would_MD have_VB
          similar_JJ effects_NNS ._. While_IN no_DT such_JJ effects_NNS were_VBD seen_VBN with_IN
          HIV-_NNP 1_CD IIIB_NNP ,_, the_DT integrity_NN of_IN HIV-_NNP 1_CD BaL_NNP appeared_VBD to_TO be_VB
          partially_RB diminished_VBN by_IN treatment_NN with_IN CAP_NNP and_CC
          drastically_RB affected_VBN by_IN cellulose_NN sulfate_NN (_( Fig_NNP ._. 6_CD )_) ._. The_DT
          latter_JJ finding_NN was_VBD confirmed_VBN by_IN the_DT observation_NN that_IN
          HIV-_NNP 1_CD BaL_NNP gp_NN 120_CD was_VBD no_DT longer_RB precipitable_JJ by_IN 3_CD %_NN PEG_NNP or_CC
          pellettable_JJ by_IN centrifugation_NN after_IN treatment_NN of_IN the_DT
          virus_NN with_IN cellulose_NN sulfate_NN ,_, unlike_IN gp_NN 120_CD associated_VBN
          with_IN untreated_JJ virus_NN particles_NNS (_( Fig_NNP ._. 7_CD )_) ._. This_DT was_VBD not_RB
          seen_VBN with_IN cellulose_NN sulfate_NN treated_VBD HIV-_NNP 1_CD IIIB_NNP (_( data_NNS not_RB
          shown_VBN )_) ._.
        
        
          Comparative_NNP virucidal_NN activity_NN of_IN polymeric_JJ anionic_JJ
          microbicide_NN candidates_NNS
          HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP ,_, respectively_RB ,_, were_VBD treated_VBN with_IN
          the_DT distinct_JJ polymers_NNS (_( 10_CD mg_NN /_NN ml_NN )_) for_IN 5_CD min_NN at_IN 37_CD °_NN C_NNP and_CC
          the_DT infectivity_NN of_IN the_DT treated_VBN viruses_NNS was_VBD compared_VBN with_IN
          that_DT of_IN control_NN untreated_JJ HIV-_NNP 1_CD ._. In_IN repeated_VBN experiments_NNS
          with_IN HIV-_NNP 1_CD IIIB_NNP ,_, soluble_JJ and_CC micronized_JJ CAP_NNP ,_, cellulose_NN
          sulfate_NN ,_, poly_RB (_( naphthalene_NN sulfonate_NN )_) ,_,
          poly_RB (_( styrene-_NN 4_CD -_: sulfonate_NN )_) and_CC BufferGel_NNP ,_, respectively_RB ,_,
          caused_VBD a_DT ≥_NN 140_CD -_: fold_VB reduction_NN in_IN infectivity_NN ,_, while_IN
          dextran_NN sulfate_NN ,_, carrageenan_NN and_CC Carbomer_NNP 974_CD P_NN (_( pH_NN 7_CD )_) ,_,
          respectively_RB ,_, were_VBD less_RBR effective_JJ (_( 4_CD -_: to_TO 25_CD -_: fold_VB
          reduction_NN in_IN infectivity_NN )_) ._. A_DT typical_JJ example_NN for_IN HIV-_NNP 1_CD
          IIIB_NNP is_VBZ shown_VBN in_IN Fig_NNP ._. 8_CD ._.
          Representative_NNP results_NNS shown_VBN in_IN Fig_NNP ._. 9_CD indicate_VBP that_IN
          the_DT polymers_NNS differed_VBD from_IN each_DT other_JJ more_RBR substantially_RB
          with_IN respect_NN to_TO their_PRP$ capacity_NN to_TO inactivate_NN HIV-_NNP 1_CD BaL_NNP ,_,
          micronized_JJ CAP_NNP ,_, cellulose_NN sulfate_NN ,_, BufferGel_NNP and_CC the_DT aryl_NN
          sulfonates_NNS being_VBG most_RBS effective_JJ ._.
        
        
          Inhibitory_NNP effect_NN of_IN polymeric_JJ anionic_JJ microbicide_NN
          candidates_NNS on_IN blood_NN clotting_VBG
          For_IN the_DT selection_NN of_IN the_DT most_RBS promising_JJ candidate_NN
          microbicides_NNS ,_, it_PRP is_VBZ important_JJ to_TO compare_VB not_RB only_RB their_PRP$
          virus_NN inhibitory_NN and_CC virucidal_NN activities_NNS ,_, but_CC to_TO also_RB
          study_VB their_PRP$ potential_JJ untoward_NN effects_NNS ._. Since_IN heparin_NN and_CC
          other_JJ anionic_JJ polymers_NNS are_VBP known_VBN to_TO inhibit_VB blood_NN
          clotting_VBG [_NN 55_CD ]_NN ,_, the_DT effect_NN of_IN anionic_JJ polymeric_JJ
          microbicide_NN candidates_NNS on_IN blood_NN clotting_VBG was_VBD measured_VBN ._.
          While_IN CAP_NNP ,_, carrageenan_NN and_CC BufferGel_NNP (_( Carbomer_NNP 974_CD P_NN )_) had_VBD
          moderate_JJ or_CC no_DT effects_NNS ,_, cellulose_NN sulfate_NN ,_, dextran_NN
          sulfate_NN ,_, poly_RB (_( napthalene_NN sulfonate_NN )_) and_CC
          poly_RB (_( styrene-_NN 4_CD -_: sulfonate_NN )_) greatly_RB inhibited_VBD clotting_VBG of_IN
          ACD_NNP plasma_NN (_( Fig_NNP ._. 10_CD )_) ._. The_DT increase_NN in_IN clotting_VBG time_NN might_MD
          be_VB potentially_RB undesirable_JJ for_IN topical_JJ applications_NNS under_IN
          conditions_NNS of_IN local_JJ preexisting_VBG injury_NN or_CC bleeding_VBG ._.
        
      
      
        Discussion_NNP
        Several_JJ anionic_JJ polymers_NNS are_VBP being_VBG considered_VBN as_IN topical_JJ
        microbicides_NNS to_TO prevent_VB sexual_JJ transmission_NN of_IN HIV-_NNP 1_CD ._. They_PRP
        include_VBP :_: (_( 1_LS )_) sulfate_NN esters_NNS of_IN polysaccharides_NNS {_( carrageenan_NN
        [_NN 1_CD 16_CD 17_CD 18_CD 19_CD ]_NN ,_, cellulose_NN sulfate_NN [_NN 12_CD 13_CD 14_CD 15_CD ]_NN ,_, and_CC
        dextran_NN or_CC dextrin_NN sulfate_NN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD ]_NN }_) ;_:
        (_( 2_LS )_) aryl_NN sulfonates_NNS {_( poly_RB (_( naphthalene_NN sulfonate_NN )_) [_NN 22_CD 23_CD 24_CD
        ]_NN and_CC poly_RB (_( styrene-_NN 4_CD -_: sulfonate_NN )_) [_NN 20_CD 21_CD ]_NN }_) ;_: and_CC (_( 3_LS )_)
        aliphatic_JJ {_( Carbomer_NNP 974_CD P_NN /_NN BufferGel_NNP [_NN 25_CD 26_CD 27_CD 28_CD 29_CD ]_NN }_) and_CC
        aromatic_JJ carboxylates_NNS {_( CAP_NNP [_NN 30_CD 31_CD 32_CD 33_CD 34_CD 35_CD 36_CD 37_CD ]_NN }_) ._.
        The_DT anti-_NN HIV-_NNP 1_CD properties_NNS of_IN these_DT polymers_NNS are_VBP expected_VBN to_TO
        depend_VB on_IN their_PRP$ complexation_NN with_IN virus_NN proteins_NNS which_WDT is_VBZ
        likely_JJ to_TO occur_VB mainly_RB through_IN the_DT formation_NN of_IN salt_NN
        linkages_NNS or_CC ion_NN pairs_NNS between_IN oppositely_RB charged_VBN groups_NNS on_IN
        the_DT polymers_NNS and_CC virus_NN proteins_NNS ,_, respectively_RB [_NN 56_CD ]_NN ._.
        However_RB ,_, the_DT anti-_NN HIV-_NNP 1_CD properties_NNS of_IN these_DT polymers_NNS may_MD
        depend_VB not_RB only_RB on_IN their_PRP$ charge_NN density_NN ,_, but_CC also_RB on_IN the_DT
        characteristics_NNS of_IN their_PRP$ uncharged_JJ portions_NNS ,_, which_WDT may_MD be_VB
        involved_VBN in_IN hydrophobic_JJ and_CC hydrogen_NN bonding_NN interactions_NNS
        which_WDT can_MD elicit_NN profound_JJ conformational_NN changes_NNS in_IN
        hydrophobic_JJ regions_NNS of_IN proteins_NNS and_CC cause_VB disassembly_RB of_IN
        complex_JJ proteins_NNS consisting_VBG of_IN subunits_NNS [_NN 57_CD ]_NN ._. For_IN these_DT
        reasons_NNS it_PRP is_VBZ not_RB be_VB expected_VBN that_IN all_DT anionic_JJ polymers_NNS ,_,
        considered_VBN as_IN anti-_NN HIV-_NNP 1_CD microbicides_NNS ,_, would_MD have_VB similar_JJ
        biological_JJ activities_NNS ._.
        
        In_IN vivo_NN protection_NN by_IN anti-_NN HIV-_NNP 1_CD
        compounds_NNS against_IN sexual_JJ transmission_NN of_IN the_DT virus_NN could_MD
        only_RB be_VB accomplished_VBN if_IN the_DT compounds_NNS at_IN sufficient_JJ
        concentrations_NNS ,_, and_CC the_DT virus_NN both_DT reach_NN susceptible_JJ cells_NNS
        within_IN genital_JJ mucosa_NN before_IN productive_JJ infection_NN could_MD
        occur_VB [_NN 38_CD 39_CD ]_NN ._. Considering_VBG the_DT complex_JJ events_NNS involved_VBN
        in_IN sexual_JJ transmission_NN of_IN HIV-_NNP 1_CD ,_, this_DT might_MD not_RB be_VB easily_RB
        accomplished_VBN ._. Therefore_RB ,_, inactivation_NN of_IN HIV-_NNP 1_CD infectivity_NN
        preceding_VBG virus_NN contact_NN with_IN susceptible_JJ target_NN cells_NNS
        should_MD be_VB considered_VBN a_DT preferred_JJ mechanism_NN of_IN protection_NN
        against_IN infection_NN ._. For_IN this_DT reason_NN it_PRP was_VBD of_IN interest_NN to_TO
        study_VB the_DT virucidal_NN activity_NN of_IN anionic_JJ polymeric_JJ
        microbicide_NN candidates_NNS against_IN both_DT X_NNP 4_CD (_( using_VBG CXCR_NNP 4_CD as_IN
        coreceptor_NN )_) and_CC R_NN 5_CD (_( using_VBG CCR_NNP 5_CD as_IN coreceptor_NN )_) viruses_NNS ,_, the_DT
        latter_JJ being_NN most_RBS frequently_RB transmitted_VBD sexually_RB [_NN 39_CD ]_NN
        ._.
        Soluble_NNP CAP_NNP at_IN neutral_JJ pH_NN was_VBD shown_VBN to_TO bind_NN strongly_RB to_TO
        the_DT coreceptor_NN binding_JJ sites_NNS on_IN gp_NN 120_CD of_IN both_DT X_NNP 4_CD and_CC R_NN 5_CD
        viruses_NNS [_NN 36_CD ]_NN and_CC to_TO elicit_NN the_DT formation_NN of_IN gp_NN 41_CD
        six-helix_JJ bundles_NNS ,_, the_DT hallmark_NN of_IN irreversible_JJ virus_NN
        inactivation_NN [_NN 37_CD ]_NN ._. Thus_RB ,_, HIV-_NNP 1_CD exposed_VBN to_TO CAP_NNP at_IN
        sufficient_JJ concentrations_NNS is_VBZ rendered_VBN noninfectious_JJ ,_, and_CC
        continued_VBD presence_NN of_IN CAP_NNP is_VBZ not_RB required_VBN to_TO maintain_VB lack_NN
        of_IN infectivity_NN ._. CAP_NNP differs_VBZ from_IN all_DT other_JJ anionic_JJ polymers_NNS
        listed_VBN above_IN ,_, in_IN that_IN it_PRP is_VBZ not_RB soluble_JJ at_IN pH_NN <_NN 5_CD ._. 5_CD ._.
        Therefore_RB ,_, CAP_NNP would_MD be_VB expected_VBN to_TO precipitate_NN in_IN a_DT normal_JJ
        acidic_JJ vaginal_JJ environment_NN ._. To_TO avoid_VB this_DT ,_, CAP_NNP in_IN
        micronized_JJ form_NN (_( which_WDT does_VBZ not_RB aggregate_JJ at_IN low_JJ pH_NN )_) ,_,
        instead_RB of_IN CAP_NNP in_IN soluble_JJ form_NN is_VBZ being_VBG considered_VBN as_IN a_DT
        topical_JJ microbicide_NN [_NN 30_CD 31_CD 32_CD 33_CD 34_CD 35_CD ]_NN ._. Micronized_NNP CAP_NNP
        (_( Aquateric_NNP )_) was_VBD shown_VBN to_TO be_VB virucidal_NN against_IN HIV-_NNP 1_CD ,_,
        herpesviruses_NNS and_CC several_JJ nonviral_NN sexually_RB transmitted_VBD
        disease_NN (_( STD_NNP )_) pathogens_NNS [_NN 30_CD 31_CD 32_CD 33_CD 34_CD ]_NN ._. The_DT virucidal_NN
        activity_NN of_IN micronized_JJ CAP_NNP could_MD at_IN least_JJS partly_RB be_VB
        explained_VBN by_IN its_PRP$ buffering_VBG capacity_NN at_IN low_JJ pH_NN [_NN 40_CD ]_NN since_IN
        it_PRP is_VBZ a_DT free_JJ acid_NN while_IN other_JJ anionic_JJ polymeric_JJ microbicide_NN
        candidates_NNS (_( except_IN BufferGel_NNP ,_, the_DT active_JJ ingredient_NN of_IN
        which_WDT is_VBZ Carbomer_NNP 974_CD P_NN [_NN 27_CD ]_NN )_) are_VBP sodium_NN salts_NNS ._. Results_NNS
        presented_VBN here_RB explain_VB how_WRB micronized_JJ CAP_NNP inactivates_NNS
        HIV-_NNP 1_CD ._. Both_DT the_DT envelope_NN glycoprotein_NN gp_NN 120_CD (_( Fig_NNP ._. 1_LS )_) and_CC
        HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP virus_NN particles_NNS (_( Fig_NNP ._. 2_LS )_) in_IN the_DT presence_NN
        of_IN an_DT excess_NN of_IN nonviral_NN proteins_NNS ,_, including_VBG seminal_NN fluid_JJ ,_,
        bind_NN effectively_RB to_TO micronized_JJ CAP_NNP ._. Under_IN 
        in_IN vivo_NN conditions_NNS (_( when_WRB the_DT virus_NN
        concentrations_NNS are_VBP by_IN one_CD to_TO four_CD orders_NNS of_IN magnitude_NN lower_JJR
        than_IN those_DT used_VBN here_RB under_IN experimental_JJ conditions_NNS [_NN 58_CD 59_CD
        ]_NN ,_, (_( Fig_NNP ._. 2_LS )_) )_) ,_, this_DT would_MD be_VB expected_VBN to_TO physically_RB remove_VB
        virus_NN particles_NNS by_IN adsorption_NN onto_IN micronized_JJ CAP_NNP
        (_( Aquateric_NNP )_) so_IN that_IN they_PRP would_MD cease_VB to_TO be_VB available_JJ to_TO
        initiate_VB the_DT complex_JJ sequence_NN of_IN events_NNS leading_VBG to_TO mucosal_NN
        infection_NN ._. Furthermore_RB ,_, interaction_NN with_IN micronized_JJ CAP_NNP
        elicits_NNS the_DT formation_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS and_CC causes_VBZ
        the_DT stripping_VBG off_RP of_IN HIV-_NNP 1_CD envelope_NN glycoproteins_NNS (_( Fig_NNP ._. 3_LS )_) ._.
        The_DT formation_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS was_VBD not_RB due_JJ to_TO
        exposure_NN to_TO a_DT low_JJ pH_NN environment_NN provided_VBN by_IN the_DT micronized_JJ
        CAP_NNP ,_, since_IN exposure_NN to_TO low_JJ pH_NN buffers_NNS did_VBD not_RB elicit_NN gp_NN 41_CD
        six-helix_JJ bundle_NN formation_NN ._. In_IN summary_NN ,_, the_DT contact_NN of_IN
        HIV-_NNP 1_CD IIIB_NNP and_CC HIV-_NNP 1_CD BaL_NNP ,_, representatives_NNS of_IN X_NNP 4_CD and_CC R_NN 5_CD
        viruses_NNS respectively_RB ,_, with_IN micronized_JJ CAP_NNP ,_, resulted_VBD in_IN a_DT
        complex_JJ sequence_NN of_IN events_NNS involving_VBG virus_NN adsorption_NN ,_,
        exposure_NN to_TO low_JJ pH_NN ,_, induction_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS ,_,
        and_CC stripping_VBG off_IN of_IN viral_JJ envelopes_NNS and_CC virus_NN
        disintegration_NN ,_, ultimately_RB resulting_VBG in_IN loss_NN of_IN
        infectivity_NN ._.
        In_IN order_NN to_TO contribute_VB to_TO the_DT understanding_NN of_IN the_DT
        potential_JJ virucidal_NN activity_NN of_IN anionic_JJ polymers_NNS ,_, their_PRP$
        capacity_NN to_TO induce_VB gp_NN 41_CD six-helix_JJ bundle_NN formation_NN was_VBD
        measured_VBN and_CC compared_VBN with_IN that_DT of_IN CAP_NNP in_IN soluble_JJ form_NN (_( pH_NN
        7_CD ._. 0_CD )_) ._. All_DT polymers_NNS except_IN Carbomer_NNP 974_CD P_NN elicited_JJ gp_NN 41_CD
        six-helix_JJ bundle_NN formation_NN in_IN HIV-_NNP 1_CD IIIB_NNP ,_, albeit_IN in_IN some_DT
        cases_NNS less_RBR efficiently_RB in_IN comparison_NN with_IN CAP_NNP (_( Fig_NNP ._. 4_LS )_) ._. On_IN
        the_DT other_JJ hand_NN ,_, gp_NN 41_CD six-helix_JJ bundle_NN formation_NN in_IN HIV-_NNP 1_CD
        BaL_NNP was_VBD detectable_JJ only_RB for_IN CAP_NNP and_CC poly_RB (_( naphthalene_NN
        sulfonate_NN )_) treated_VBN virus_NN (_( Fig_NNP ._. 5_LS )_) suggesting_VBG differences_NNS
        among_IN the_DT anionic_JJ polymers_NNS with_IN respect_NN to_TO their_PRP$ activity_NN
        against_IN the_DT R_NN 5_CD virus_NN HIV-_NNP 1_CD BaL_NNP ._. The_DT induction_NN of_IN six-helix_JJ
        bundles_NNS in_IN HIV-_NNP 1_CD does_VBZ not_RB seem_VB to_TO be_VB the_DT only_JJ mechanism_NN
        involved_VBN in_IN virucidal_NN activity_NN of_IN anionic_JJ polymers_NNS (_( compare_VB
        Fig_NNP ._. 5_LS with_IN Figs_NNP ._. 8_CD and_CC 9_CD )_) and_CC there_EX might_MD be_VB other_JJ
        contributing_VBG processes_NNS ._.
        Since_IN CAP_NNP in_IN micronized_JJ form_NN was_VBD shown_VBN to_TO cause_VB
        disintegration_NN of_IN HIV-_NNP 1_CD virus_NN particles_NNS [_NN 31_CD ]_NN ,_, (_( Fig_NNP ._. 3_LS )_) ,_,
        it_PRP was_VBD of_IN interest_NN to_TO determine_VB whether_IN any_DT of_IN the_DT other_JJ
        anionic_JJ polymeric_JJ microbicide_NN candidates_NNS affect_VBP the_DT
        integrity_NN of_IN virus_NN particles_NNS ._. While_IN HIV-_NNP 1_CD IIIB_NNP was_VBD not_RB
        affected_VBN significantly_RB by_IN any_DT of_IN the_DT polymers_NNS tested_VBN ,_, CAP_NNP
        to_TO some_DT extent_NN ,_, but_CC surprisingly_RB cellulose_NN sulfate_NN affected_VBD
        the_DT integrity_NN of_IN HIV-_NNP 1_CD BaL_NNP particles_NNS (_( Fig_NNP ._. 6_CD )_) ._. These_DT
        results_NNS were_VBD supported_VBN by_IN the_DT observation_NN that_IN HIV-_NNP 1_CD BaL_NNP
        gp_NN 120_CD after_IN treatment_NN with_IN cellulose_NN sulfate_NN ,_, unlike_IN virus_NN
        associated_VBN gp_NN 120_CD ,_, did_VBD not_RB become_VB precipitated_VBD with_IN 3_CD %_NN PEG_NNP
        and_CC failed_VBD to_TO pellet_NN by_IN centrifugation_NN under_IN conditions_NNS
        leading_VBG to_TO sedimentation_NN of_IN intact_JJ virus_NN particles_NNS (_( Fig_NNP ._.
        7_CD )_) ]_NN ._. The_DT differential_NN sensitivity_NN of_IN an_DT R_NN 5_CD virus_NN ,_, HIV-_NNP 1_CD
        BaL_NNP ,_, as_IN compared_VBN to_TO an_DT R_NN 4_CD virus_NN ,_, HIV-_NNP 1_CD IIIB_NNP ,_, to_TO the_DT same_JJ
        negatively_RB charged_VBN polyelectrolyte_NN appears_VBZ unprecedented_JJ to_TO
        the_DT best_JJS of_IN our_PRP$ knowledge_NN ._.
        Among_IN the_DT three_CD polysaccharide_NN sulfate_NN esters_NNS
        (_( carrageenan_NN ,_, cellulose_NN sulfate_NN and_CC dextran_NN sulfate_NN )_) ,_,
        cellulose_NN sulfate_NN appeared_VBD to_TO be_VB more_RBR effective_JJ against_IN
        HIV-_NNP 1_CD BaL_NNP than_IN the_DT other_JJ polymers_NNS ._. This_DT might_MD be_VB due_JJ to_TO the_DT
        polysaccharide_NN backbone_NN of_IN cellulose_NN [_NN 60_CD ]_NN with_IN a_DT
        propensity_NN to_TO form_VB strong_JJ intermolecular_NN hydrogen_NN bonds_NNS and_CC
        to_TO be_VB involved_VBN in_IN hydrophobic_JJ interactions_NNS more_JJR than_IN
        soluble_JJ dextrans_NNS [_NN 61_CD ]_NN and_CC galactose_NN +_NN
        3_CD ,_, 6_CD -_: anhydrogalactose_NN copolymers_NNS (_( =_SYM the_DT saccharide_NN moiety_NN of_IN
        carrageenan_NN )_) [_NN 62_CD 63_CD ]_NN ._. Among_IN the_DT two_CD polymers_NNS containing_VBG
        aryl_NN sulfonates_NNS ,_, poly_RB (_( napthalene_NN sulfonate_NN )_) was_VBD more_RBR
        effective_JJ than_IN poly_RB (_( styrene-_NN 4_CD -_: sulfonate_NN )_) with_IN respect_NN to_TO
        induction_NN of_IN gp_NN 41_CD six-helix_JJ bundles_NNS in_IN HIV-_NNP 1_CD BaL_NNP ._. This_DT
        difference_NN may_MD possibly_RB be_VB due_JJ to_TO the_DT high_JJ propensity_NN of_IN
        the_DT uncharged_JJ part_NN of_IN the_DT molecule_NN {_( poly_RB (_( naphtalene_NN )_) }_) to_TO be_VB
        involved_VBN in_IN hydrophobic_JJ interactions_NNS ._. Among_IN the_DT two_CD
        carboxylate_NN polymers_NNS (_( Carbomer_NNP 974_CD P_NN and_CC CAP_NNP )_) ,_, only_RB soluble_JJ
        CAP_NNP (_( at_IN neutral_JJ pH_NN )_) was_VBD able_JJ to_TO elicit_NN the_DT formation_NN of_IN
        gp_NN 41_CD six-helix_JJ bundles_NNS in_IN both_DT HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP and_CC was_VBD
        virucidal_NN against_IN both_DT of_IN these_DT viruses_NNS ._. The_DT insoluble_JJ ,_,
        micronized_JJ form_NN of_IN CAP_NNP had_VBD similar_JJ properties_NNS ._. The_DT
        differences_NNS in_IN biological_JJ activities_NNS of_IN these_DT polymers_NNS is_VBZ
        probably_RB due_JJ to_TO their_PRP$ noncharged_JJ portions_NNS ,_, i_NNP ._. e_SYM ._. mainly_RB the_DT
        occurrence_NN of_IN benzene_NN rings_NNS in_IN CAP_NNP ._.
        Polycarboxylates_NNP (_( soluble_JJ CAP_NNP and_CC Carbomer_NNP 974_CD P_NN ;_: Fig_NNP ._.
        10_CD )_) had_VBD a_DT minimal_JJ effect_NN on_IN plasma_NN coagulation_NN ._. Among_IN the_DT
        sulfonates_NNS and_CC polysaccharide_NN sulfates_NNS ,_, carrageenan_NN and_CC
        poly_RB (_( napthalene_NN sulfonate_NN )_) had_VBD lower_JJR anti-coagulant_JJ
        activity_NN in_IN comparison_NN with_IN cellulose_NN sulfate_NN ,_, dextran_NN
        sulfate_NN and_CC poly_RB (_( styrene-_NN 4_CD -_: sulfonate_NN )_) (_( Fig_NNP ._. 10_CD )_) ._.
        Consideration_NNP of_IN these_DT side_NN effects_NNS might_MD contribute_VB to_TO the_DT
        process_NN of_IN selection_NN of_IN preferred_VBN microbicides_NNS for_IN future_JJ
        large-scale_JJ use_NN ._.
      
      
        Conclusions_NNP
        Among_IN anionic_JJ polymers_NNS considered_VBN as_IN topical_JJ
        microbicides_NNS to_TO prevent_VB sexual_JJ transmission_NN of_IN HIV-_NNP 1_CD
        {_( Carbomer_NNP 974_CD P_NN /_NN BufferGel_NNP ,_, carrageenan_NN ,_, CAP_NNP ,_, cellulose_NN
        sulfate_NN ,_, dextran_NN /_NN dextrin_NN sulfate_NN ,_, poly_RB (_( napthalene_NN
        sulfonate_NN )_) and_CC poly_RB (_( styrene-_NN 4_CD -_: sulfonate_NN )_) }_) ,_, CAP_NNP formulated_VBN
        in_IN a_DT micronized_JJ form_NN ,_, is_VBZ the_DT only_JJ compound_NN which_WDT has_VBZ a_DT
        capacity_NN to_TO remove_VB from_IN physiological_JJ fluids_NNS infectious_JJ
        virus_NN by_IN adsorption_NN onto_IN the_DT micronized_JJ particles_NNS ._. The_DT
        interaction_NN between_IN HIV-_NNP 1_CD IIIB_NNP ,_, a_DT representative_NN of_IN X_NNP 4_CD
        viruses_NNS ,_, and_CC HIV-_NNP 1_CD BaL_NNP ,_, a_DT representative_NN of_IN R_NN 5_CD viruses_NNS ,_,
        with_IN the_DT micronized_JJ form_NN of_IN CAP_NNP has_VBZ the_DT following_JJ
        consequences_NNS :_: 1_LS )_) elicitation_NN of_IN "_'' dead-end_JJ "_'' gp_NN 41_CD six-helix_JJ
        bundles_NNS expected_VBN to_TO render_VB the_DT virus_NN incompetent_JJ to_TO fuse_NN
        with_IN target_NN cells_NNS ;_: 2_LS )_) loss_NN of_IN virus_NN integrity_NN and_CC stripping_VBG
        off_RP of_IN the_DT envelope_NN glycoproteins_NNS ;_: and_CC 3_LS )_) inactivation_NN of_IN
        virus_NN infectivity_NN ._. Elicitation_NNP of_IN gp_NN 41_CD six-helix_JJ bundles_NNS
        and_CC virucidal_NN activity_NN represent_VB shared_VBN properties_NNS between_IN
        micronized_JJ and_CC soluble_JJ (_( at_IN sufficient_JJ concentrations_NNS )_) forms_NNS
        of_IN CAP_NNP [_NN 37_CD ]_NN ._.
        As_IN determined_VBN by_IN ELISA_NNP ,_, the_DT aforementioned_JJ polymers_NNS
        other_JJ than_IN CAP_NNP (_( except_IN Carbomer_NNP 974_CD P_NN )_) also_RB elicited_JJ gp_NN 41_CD
        six-helix_JJ bundle_NN formation_NN in_IN HIV-_NNP 1_CD IIIB_NNP ,_, albeit_IN less_RBR
        effectively_RB than_IN CAP_NNP ._. On_IN the_DT other_JJ hand_NN ,_, only_RB
        poly_RB (_( napthalene_NN sulfonate_NN )_) ,_, in_IN addition_NN to_TO CAP_NNP ,_, elicited_JJ
        detectable_JJ six-helix_JJ bundle_NN formation_NN in_IN HIV-_NNP 1_CD BaL_NNP ._. This_DT
        suggests_VBZ that_IN X_NNP 4_CD and_CC R_NN 5_CD viruses_NNS may_MD be_VB differently_RB affected_VBN
        by_IN some_DT of_IN the_DT polymeric_JJ compounds_NNS being_VBG considered_VBN as_IN
        topical_JJ microbicides_NNS ._. This_DT was_VBD confirmed_VBN by_IN the_DT results_NNS of_IN
        assays_NNS for_IN virucidal_NN activity_NN ._.
      
      
        Abbreviations_NNP used_VBD
        ACD_NNP ,_, acid_NN citrate_NN dextrose_NN ;_: CAP_NNP ,_, cellulose_NN acetate_NN
        phthalate_NN ;_: BSA_NNP ,_, bovine_JJ serum_NN albumin_NN ;_: DMEM_NNP ,_, Dulbecco_NNP 's_POS
        modified_VBN Eagle_NNP medium_NN ;_: ELISA_NNP ,_, enzyme-linked_JJ immunosorbent_NN
        assay_NN ;_: FBS_NNP ,_, fetal_JJ bovine_JJ serum_NN ;_: HIV-_NNP 1_CD ,_, human_JJ
        immunodeficiency_NN virus_NN type_NN 1_CD ;_: HRP_NNP ,_, horseradish_NN peroxidase_NN ;_:
        mAb_NN ,_, monoclonal_NN antibodies_NNS ;_: PEG_NNP 6000_CD ,_, polyethylene_NN glycol_NN
        6000_CD ;_: PBS_NNP ,_, phosphate_NN buffered_JJ saline_NN ;_: PBS-BG_NNP ,_, 1_CD %_NN BSA_NNP /_NN 1_CD %_NN
        gelatin_NN in_IN PBS_NNP ;_: sCD_NN 4_CD ,_, soluble_JJ CD_NNP 4_CD ;_: STD_NNP ,_, sexually_RB
        transmitted_VBD disease_NN ;_: TS_NNP ,_, 0_CD ._. 14_CD M_NNP NaCl_NNP ,_, 0_CD ._. 01_CD M_NNP Tris_NNP ,_, pH_NN
        7_CD ._. 0_CD ;_:
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN 1_CD ARN_NNP developed_VBD the_DT concepts_NNS representing_VBG the_DT
        basis_NN of_IN the_DT manuscript_NN and_CC designed_VBN most_JJS experiments_NNS ._.
        Author_NN 2_CD NS_NNP carried_VBD out_IN most_JJS experiments_NNS and_CC contributed_VBD to_TO
        the_DT development_NN of_IN experimental_JJ techniques_NNS ._. Author_NN 3_CD YYL_NNP
        did_VBD all_PDT the_DT tissue_NN culture_NN work_NN and_CC infectivity_NN assays_NNS ._.
      
    
  
